Successful treatment of visceral leishmaniasis with liposomal amphotericin B
Heimo Lagler1, Ulrich Matt, Christian Sillaber
1Department of Internal Medicine I, Division of Infectious Diseases and Chemotherapy, Medical University of Vienna, Austria.
Acta Bio-Medica : Atenei Parmensis
|August 22, 2006
Abstract:
We report a case of a 26-year-old female from Kenya who suffered from intermittent fever of unknown origin for one month. The major findings on admission were pancytopenia associated with considerable splenomegaly. The diagnosis was established by visualisation of amastigotes in bone marrow biopsy and by detection of antibodies to Leishmania spp. in blood. The infection was treated intravenously with liposomal amphotericin B for five days. The patient was afebrile after the first infusion. No relapse was reported.
Related Concept Videos
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...